diagnostics: search

Enigma Diagnostics Announces Patent Licence With Applied Biosystems

Enigma Diagnostics Limited announced that it has signed a third licence agreement with Applied Biosystems.

Paternity Testing Leader DNA Diagnostics Center Acquired by MTS Health Investors

New York-based private equity firm MTS Health Investors has acquired DNA Diagnostics Center (DDC; Fairfield, Ohio), a leading provider of genetic testing. Ellen Moscovitz, formerly head of LabCorp’s DNA testing operations, has been tapped as CEO, and Michael Baird, M.D., will continue on as the laboratory director. Financial terms of the acquisition were not disclosed.

11/04/08 - Paternity Testing Leader DNA Diagnostics Center Acquired by MTS Health Investors

New York-based private equity firm MTS Health Investors has acquired DNA Diagnostics Center (DDC; Fairfield, Ohio), a leading genetic testing provider. Ellen Moscovitz, formerly head of LabCorp’s DNA testing operations, has been tapped as CEO, and Michael Baird, M.D., will continue on as the laboratory director. Financial terms of the acquisition were not disclosed.

DNA Probes-Based Diagnostics Market Projected to Reach $24.5 Billion by 2015

J. Craig Venter Institute Becomes A Partner For Raindance's RDT 1000 Instrument And Sequence Enrichment Application

Researchers at UH explore patient preferences for personalized medicine

Study will identify genomic diagnostics in use, evaluate trade-offs patients make for greater treatment precision

Hand Exercising Robot Helps Stroke Patients Regain Brain Function After 6 Months

Also Included In: Medical Devices / Diagnostics; MRI / PET / Ultrasound; Radiology / Nuclear Medicine

Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing

PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostics company, announced that the U.S. Patent and Trademark Office (USPTO) has issued two separate patents covering the technology for PROMETHEUS(R) Thiopurine Metabolites, a diagnostic test that enables physicians to optimize ongoing dosing of thiopurines to reach and maintain desired therapeutic levels. The USPTO has approved the issuance of the claims in U.S. Patent Nos. 7,425,546 and 7,429,570, both entitled, "Methods of optimizing drug therapeutic efficacy for treatment of immune- mediated gastrointestinal disorders."

Stroke Rehabilitation Improved By Robotic Technology

Also Included In: Rehabilitation / Physical Therapy; Medical Devices / Diagnostics; MRI / PET / Ultrasound

Rosetta Genomics Launches Plant Biotech Initiative to Leverage microRNA Technologies; Potential Focus on Algal Oil Enhancement

Rosetta Genomics Ltd., a leading developer of microRNA-based diagnostics and therapeutics, has launched Rosetta Green, a microRNA-based plant biotechnology project. Rosetta Green will leverage the knowledge gained at Rosetta Genomics in microRNAs (miRNAs)—a group of short (21–23 nucleotides in length), non-coding genes which regulate the expression of other genes—to develop a wide range of plant-based applications. The company recently completed a financing round from private investors exclusively for this project.

PerkinElmer names new vice president of cellular imaging and analysis

PerkinElmer, a provider of technology, services and solutions to the diagnostics, detection and analysis and photonics markets, has appointed Achim Leoprechting as its new vice president and general manager of cellular imaging and analysis solutions.

An Easy Pill to Swallow

Research is showing that nanotechnology may be the next “big thing� for drug delivery and diagnostics.

Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative

REHOVOT, Israel and JERSEY CITY, New Jersey, October 27 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading developer of microRNA-based diagnostics and therapeutics, announced today it has launched Rosetta Green, a microRNA-based plant biotechnology project. Rosetta Green will leverage the extensive knowledge gained at Rosetta Genomics in microRNAs, as well as its proprietary technologies and strong IP position, to develop a wide range of plant-based applications. The company has recently completed a financing round from private investors exclusively for this project.

SERS-Melting: A New Method for Discriminating Mutations in DNA Sequences

The reliable discrimination of mutations, single nucleotide polymorphisms (SNPs), and other differences in genomic sequence is an essential part of DNA diagnostics and forensics. It is commonly achieved using fluorescently labeled DNA probes and thermal gradients to distinguish between the matched and mismatched DNA. Here, we describe a novel method that uses surface enhanced (resonance) Raman spectroscopy (SER(R)S) to follow denaturation of dsDNA attached to a structured gold surface. This denaturation is driven either electrochemically or thermally on SERS active sphere segment void (SSV) gold substrates. Using this method, we can distinguish between wild type, a single point mutation (1653C/T), and a triple deletion (ΔF 508) in the CFTR gene at the 0.

Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative

REHOVOT, Israel and JERSEY CITY, New Jersey, October 27 /PRNewswire/ -- Rosetta Genomics Ltd (NASDAQ: ROSG) , a leading developer of microRNA-based diagnostics and therapeutics, announced today it has launched Rosetta Green, a microRNA-based plant biotechnology project. Rosetta Green will leverage the extensive knowledge gained at Rosetta Genomics in microRNAs, as well as its proprietary technologies and strong IP position, to develop a wide range of plant-based applications. The company has recently completed a financing round from private investors exclusively for this project.

ITC 2008: Cadence assists Hitachi with 300X compression, Moai with fast tapeout

Cadence Design Systems at the International Test Conference said Hitachi has combined Encounter Test pattern-fault modeling with test pattern generation, compression, and diagnostics to produce LSI devices for telecommunications and other applications. Cadence also said that Moai Electronics, an IC design company in Taiwan, has deployed Cadence Encounter RTL Compiler and Encounter Test to successfully tape out a flash memory controller.

ITC: Cadence assists Hitachi with 300X compression, Moai with fast tapeout

Cadence Design Systems at the International Test Conference said Hitachi has combined Encounter Test pattern-fault modeling with test pattern generation, compression, and diagnostics to produce LSI devices for telecommunications and other applications. Cadence also said that Moai Electronics, an IC design company in Taiwan, has deployed Cadence Encounter RTL Compiler and Encounter Test to successfully tape out a flash memory controller.

QIAGEN and Institute for Animal Health Enter Partnership in Bluetongue Testing

QIAGEN N.V. has announced that it has entered into a worldwide exclusive partnership with the Institute for Animal Health (IAH), a research and diagnostics institution for infectious diseases of farm animals. Pursuant to the agreement QIAGEN has licensed a novel molecular assay design for bluetongue, a viral disease among ruminants such as sheep and cattle. The cador BTV RT-PCR Kit, which was developed by the IAH, will be launched by QIAGEN in 2009 and further expand the company's veterinary testing portfolio.

Lecture engages in importance of intellectual property

The Law and Science Student Association hosts Rod Fuller, a member of Fennemore Craig’s intellectual property and life sciences practice, which includes biotechnology, pharmaceuticals, medical devices, and diagnostics.Â

Search took 0.02 seconds.